Mycobacterial Lung Diseases in Virginia: Sequencing and Clinical Determinants of Relapse and Outcome

Description

Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome

Conditions

Nontuberculous Mycobacterial Lung Disease

Study Overview

Study Details

Study overview

Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome

Mycobacterial Lung Diseases in Virginia: Sequencing and Clinical Determinants of Relapse and Outcome

Mycobacterial Lung Diseases in Virginia: Sequencing and Clinical Determinants of Relapse and Outcome

Condition
Nontuberculous Mycobacterial Lung Disease
Intervention / Treatment

-

Contacts and Locations

Charlottesville

University of Virginia, Division of Infectious Disease, Charlottesville, Virginia, United States, 22908

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All subjects:
  • * Race/ethnicity: any
  • * Subject has no history of active Tuberculosis in the last 2 years.
  • * NTM culture positive from respiratory specimen (sputum or bronchial lavage fluid)
  • * Subject must have an available sputum sample that was taken in the last 2 years. If a sample is not available, the subject must be willing and able to provide a sputum sample.
  • * Meets the following Infectious Diseases Society of America (IDSA) criteria for NTM lung disease:
  • * 2 or more sputum (or 1 bronchoscopy/biopsy) cultures positive for "Mycobacterium Avium Complex" or "Mycobacterium abscessus) within the last 2 years.
  • * Nodules, cavities, and/or bronchiectasis on CT scan within the past 2 years
  • * If if the above data are not available, but a patient's Infectious Disease or Pulmonary physician has documented the diagnosis of NTM lung disease in their notes, this will suffice
  • * Newly diagnosed with NTM lung disease and beginning antibiotics for NTM within the last 3 months from enrollment.
  • * Prior diagnosis of NTM lung disease, and starting initial therapy within the last 3 months prior to enrollment.
  • * Consent to pharmacokinetic testing within one month of enrollment and at six months of therapy
  • * List the criteria for exclusion
  • * Age \< 18 years
  • * Subject has cystic fibrosis or other inherited disorders of airway ciliary dysfunction (eg, primary ciliary dyskinesia)
  • * Unable to participate in follow-up requirements by phone or clinic visit

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Virginia,

Study Record Dates

2026-12-31